AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 16 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2019, AMAG Pharmaceuticals, Inc. reported significant carbon emissions, with Scope 1 emissions totalling approximately 104,400,000 kg CO2e and Scope 3 emissions reaching about 1,200,000,000 kg CO2e. The company has disclosed emissions data for Scope 1, 2, and 3, indicating a comprehensive approach to understanding its carbon footprint. In the preceding years, AMAG's emissions showed a slight decline, with Scope 1 emissions at about 101,000,000 kg CO2e in 2018 and 104,400,000 kg CO2e in 2017. However, there is no available data for emissions in 2021 and 2022, which may suggest a gap in reporting or data collection during those years. Despite the absence of specific reduction targets or initiatives, AMAG's commitment to monitoring and reporting its emissions reflects an awareness of climate impact. The company has not publicly committed to any science-based targets or climate pledges, which may limit its ability to demonstrate leadership in sustainability within the pharmaceutical industry. Overall, AMAG Pharmaceuticals, Inc. is positioned to enhance its climate commitments and reduction strategies, particularly in light of the growing emphasis on corporate responsibility regarding carbon emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | |
|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AMAG Pharmaceuticals, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
